14 گھنٹے پہلے
New Hope declares fully franked 30c final dividend; Telix strikes scrip merger valued up to US$2.35bn
New Hope Corporation declared a fully franked 30c per share final dividend, exceeding expectations, supported by strong operations and a year-end cash balance of A$485m. Telix Pharmaceuticals announced a scrip-based merger with Germany’s privately owned ITM Group, with consideration of up to US$2.35bn. REA Group also drew a fresh analyst rating.
14 گھنٹے پہلے
2 دن پہلے
BHP shares jump 51.7% year on year as FY 2026 dividends rise to $2.419 a share
BHP Group shares have gained 51.7% over the past 12 months, outperforming the ASX 200 by more than 52 percentage points. The miner’s FY 2026 dividend payouts totalled $2.419 per share, up 41.6% year on year, implying a fully franked trailing dividend yield of 4% at current prices. Copper became BHP’s largest earnings driver for the first time, helped by a near-40% rise in copper prices in H2 FY26.
2 دن پہلے
9-21
BHP shares jump 53% in 12 months as copper tops half of FY 2026 underlying EBITDA
BHP’s share price has risen 53% over the past year. In FY 2026, copper contributed more than half of underlying EBITDA for the first time, with production of roughly 2 million tonnes, and the company’s copper growth pipeline is expected to lift attributable output by around 40% by FY 2035. BHP is also targeting annual iron ore production above 305 million tonnes. In Canada, the Jansen potash project was 84% complete and is scheduled for first production in mid2027, with an expected operating life beyond 60 years.
9-21
9-21
Telix to buy ITM for US$1.65 billion upfront, with up to US$700 million in milestones
Telix Pharmaceuticals said it will acquire 100% of ITM for US$1.65 billion upfront, with up to US$700 million in milestone payments. ITM reported US$273 million in 2025 revenue and a 40% CAGR from 2021–2025. On a pro forma basis, the combined group is projected to generate more than US$1.3 billion in 2026 revenue, with Telix shareholders expected to own about 76.3% after completion. The deal remains subject to shareholder and regulatory approvals, with closing expected by the end of FY2026.
9-21
9-21
Bell Potter cuts New Hope to sell with a $5.00 target after FY26 profit miss
Australia coal producer New Hope Corporation Ltd (ASX: NHC) reported FY26 underlying EBITDA of $514m and statutory NPAT of $161m, coming in below expectations due to higher finance expenses. The company realised an average coal price of A$145/t and an average group FOB cash cost (excluding royalties) of A$89/t, with underlying profit down 30% year on year. It declared a 30cps fully franked final dividend despite the weaker result. The stock has since been downgraded by a broker to a sell rating.
9-21
9-18
Woodside projects FY26 EPS at $2.184 as Scarborough nears completion, CommSec forecast shows
Woodside Energy reported FY26 operating revenue rose 13% to US$7.4 billion, while underlying NPAT increased 7% to $1.3 billion and free cash flow jumped 159% to $352 million. The company said a 20% lift in average realised prices to US$74 per barrel of oil equivalent partly offset a 13% drop in production to 86.5 million barrels of oil equivalent. Woodside also updated progress on key developments, with Scarborough 98% complete, Trion 64% and Louisiana LNG 28% complete. CommSec forecasts FY26 EPS of $2.184 and projects FY28 EPS could fall 5% to $2.52, according to its estimates.
9-18
9-18
Macquarie flags 57% upside for ASX-listed Nickel Industries
Macquarie analysts said Nickel Industries lifted first-half revenue 13.1% year-on-year to US$938.4 million, while net profit jumped 365.8% to US$52.5 million. The company’s ENC project has been disrupted by water-supply constraints, but it ramped to about 50% of nameplate capacity early in commissioning. At the Hengjaya mine, August nickel sales hit a record 1.6 million tonnes. Based on combined adjusted EBITDA of about US$90 million for July and August, Macquarie said the shares look undervalued and pointed to 57% potential upside.
9-18
9-17
Telix gains attention after FDA clears Pixclara as CSL rallies 31% to A$176.50
CSL shares have rebounded about 31% over the past month to A$176.50, but the A$159.86 average target price implies around 8% downside. The company reported FY26 revenue of US$15.8 billion and NPAT of US$2.6 billion, while also booking a net loss after tax of US$2.6 billion driven by impairments and restructuring costs. Management described FY26 as a “reset year” and said FY27 should mark a return to growth, while adjusted EBITDA rose 146% year on year to US$52 million.
9-17